CDEX, Inc. (CEXI.OB) Signs Distribution Agreement with HealthContrax to Expand U.S. Market Reach

QualityStocks would like to highlight CDEX, Inc. (OTCBB: CEXI). CEDEX develops, manufactures, and globally distributes products to the healthcare and security markets. The ValiMed product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched.

In the company’s news Friday,

CDEX Inc. announced it has entered into a distribution agreement with HealthContrax LLC, an Iowa-based national accounts sales agency.

HealthContrax acts as a National Account representative agency that helps healthcare manufacturers gain market access by connecting both large and small healthcare manufacturers to the various channels they serve. This effectively extends marketing reach and distribution for their manufacturing partners.

Per the agreement, CDEX has access to Group Purchasing Organizations (GPOs) that contract for thousands of hospitals, labs and clinics across the country. Through its partnership with HealthContrax, CDEX also has immediate, nationwide market access for its ValiMed™ Validation System product line.

“The distribution partnership with HealthContrax grants access to national Group Purchasing Organizations that contract with thousands of hospitals domestically, directly extending the sales reach for our ValiMed Validation Systems,” Jeff Brumfield, CEO and chairman of the board of CDEX stated in the press release. “We believe HealthContrax is a great distribution partner and brings immediate access to agencies across the U.S., which should accelerate interest in our systems.”

Marc Marchand, CEO of HealthContrax, voiced his position that ValiMed Validation Systems will have a solid foothold in the healthcare market.

“We met with the CDEX team at the ASHP Midyear Conference and were very impressed with the ValiMed Validation Systems,” Marchand stated. “We believe the ValiMed has tremendous market potential as hospitals and other healthcare agencies focus on patient safety and drug loss prevention.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.